Overview

An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome

Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the overall response rate (ORR) and safety when treating patients with myelodysplastic syndrome with decitabine. Decitabine is to be administered as long as there is evidence of clinical benefit.
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Azacitidine
Decitabine